---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-042537"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:17:22.403402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech: 84.4% 36-month OS in cervical cancer trial of Versamune HPV + chemoradiation

## Summary
- 36-month OS rate 84.4% (all patients) vs ~64% historical; 100% in 8 patients receiving all 5 doses.
- 36-month PFS rate 74.9% overall, 100% in fully dosed subgroup; historical ~61%.
- Complete metabolic response (CMR) in 88% (15/17) of patients at 4 months per PET.
- Versamune HPV well-tolerated; most common related AE injection site reaction (71%).
- Median follow-up 19 months; data presented at ASTRO 2024, awarded Basic/Translational Science Award.

## SEC filing metadata
- accession: 0001140361-24-042537
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124042537/0001140361-24-042537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124042537/ef20036539_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-042537
- JSON: https://secwatch.observer/filing/0001140361-24-042537.json
- Plain text: https://secwatch.observer/filing/0001140361-24-042537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.